Neuropathy. Drug-induced polyneuropathy
Conditions
Interventions
Intervention 1: Intervention group: Patients received one oral capsule of Curcumin (manufactured by Dineh Company, Iran) every 12 hours (with a dose of 3 mg/kg) for 3 months. Intervention 2: Placebo g
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
5 Years to 18 Years
Inclusion criteria
Inclusion criteria: Consent of parents or children older than 13 years to participate in the study Age range from 5 to 18 years Children who have recently been diagnosed with ALL and have not yet started treatment with vincristine
Exclusion criteria
Exclusion criteria: Congenital malformations and developmental disoreders Primary central nervous system involvement History of taking anti-inflammatory and antioxidant drugs Under treatment with other drugs leading to nephropathy Presence of neuropathy before treatment with vincristine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Presence or absence of neuropathy. Timepoint: Before intervention and 3 months after the intervention. Method of measurement: EMG, NCV and the 12 canial nerve examinations. | — |
Secondary
| Measure | Time frame |
|---|---|
| Severity of neuropathy. Timepoint: Before intervention and 3 months after the intervention. Method of measurement: EMG, NCV and clinical examinations of 12 nerves. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contact?Aziz Eghbali
Iran University of Medical Sciences
Outcome results
None listed